High dose of depot risperidone in a nonresponder schizophrenic patient [3]

Journal of Clinical Psychopharmacology

Volumn 24, Issue 6, 2004, Pages 673-674

  Albrecht, Anaïs ^a   Morena, Perla G ^a   Baumann, Pierre ^a   Eap, Chin B ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDONE CHLORHYDRATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLORAZEPATE; FLUOXETINE; FLUPENTIXOL; PENFLURIDOL; RISPERIDONE; THIORIDAZINE; UNCLASSIFIED DRUG; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL ACETATE;

ADULT; CASE REPORT; DEVICE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETTER; MALE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; TREMOR;

ADULT; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA;

EID: 8744240473     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000145347.68664.4e     Document Type: Letter

References (10)

1. Eap CB, Buclin T, Cucchia G, et al. Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol. 2004;60:237-246.
2. Eap CB, Bouchoux G, Powell Golay K, et al. Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry. Journal of Chromatography B. 2004;802:339-345.
3. Eap CB, Gaillard N, Powell K, et al. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas-chromatography-mass spectrometry. J Chromatogr Biomed Appl. 1996;682:265-272.
4. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990;336:529-532.
5. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30-34.
6. Aravagiri M, Marder SR, Wirshing D, et al. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry. 1998;31:102-109.
7. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001;29(9):1263-1268.
8. Bondolfi G, Eap CB, Bertschy G, et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry. 2002;35:50-56.
9. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitor. Clin Pharmacokinet. 1996;31:444-469.
10. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11:573-585.